Key result
Heterozygous S6K1 missense variants linked to hypertrophic cardiomyopathy via gain-of-function signaling.
Why the study?
The genetic impact of signalling proteins on hypertrophic cardiomyopathy (HCM) is relatively unknown compared to sarcomeric protein-encoding gene mutations.
Case-Control (n=20,592)
Yes
Variants in signalling proteins enriched among Indian HCM cases; leaves open pathogenicity, replication, and clinical utility.
Background Hypertrophic cardiomyopathy (HCM) is a genetic heart muscle disease with preserved or increased ejection fraction in the absence of secondary causes. Mutations in the sarcomeric protein-encoding genes predominantly cause HCM. However, relatively little is known about the genetic impact of signalling proteins on HCM. Methods and results Here, using exome and targeted sequencing methods, we analysed two independent cohorts comprising 401 Indian patients with HCM and 3521 Indian controls. We identified novel variants in ribosomal protein S6 kinase beta-1 (RPS6KB1 or S6K1) gene in two unrelated Indian families as a potential candidate gene for HCM. The two unrelated HCM families had the same heterozygous missense S6K1 variant (p.G47W). In a replication association study, we identified two S6K1 heterozygotes variants (p.Q49K and p.Y62H) in the UK Biobank cardiomyopathy cohort (n=190) compared with matched controls (n=16 479). These variants are neither detected in region-specific controls nor in the human population genome data. Additionally, we observed an S6K1 variant (p.P445S) in an Arab patient with HCM. Functional consequences were evaluated using representative S6K1 mutated proteins compared with wild type in cellular models. The mutated proteins activated the S6K1 and hyperphosphorylated the rpS6 and ERK1/2 signalling cascades, suggesting a gain-of-function effect. Conclusions Our study demonstrates for the first time that the variants in the S6K1 gene are associated with HCM, and early detection of the S6K1 variant carriers can help to identify family members at risk and subsequent preventive measures. Further screening in patients with HCM with different ethnic populations will establish the specificity and frequency of S6K1 gene variants.
No takes yet. Share an insight, caveat, or question.
Jayappa et al. (2021) conducted a case-control in Hypertrophic cardiomyopathy (HCM) (n=20,592). S6K1 (RPS6KB1) gene variants vs. Wild type / matched controls was evaluated on Presence of S6K1 gene variants in HCM patients compared to controls and their functional consequences. Heterozygous missense variants in the S6K1 gene were associated with hypertrophic cardiomyopathy across independent Indian and UK cohorts and induced gain-of-function signaling in cellular models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: